<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37351631</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1420-908X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Inflammation research : official journal of the European Histamine Research Society ... [et al.]</Title><ISOAbbreviation>Inflamm Res</ISOAbbreviation></Journal><ArticleTitle>SHP2: its association and roles in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>1501</StartPage><EndPage>1512</EndPage><MedlinePgn>1501-1512</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00011-023-01760-w</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease. Src homology 2 domain containing protein tyrosine phosphatase (SHP2) is a member of the protein tyrosine phosphatases (PTPs) family. To date, relationship between SHP2 and SLE pathogenesis is not elucidated.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We measured plasma levels of SHP2 in 328 SLE patients, 78 RA patients, 80 SS patients and 79 healthy controls by ELISA, and discussed association of SHP2 in SLE patients, potential of plasma SHP2 as a SLE biomarker. Moreover, histological and serological changes were evaluated by flow cytometry, HE/Masson examination, immunofluorescence test in pristane-induced lupus mice after SHP2 inhibitor injection to reveal role of SHP2 in lupus development.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results indicated that SHP2 plasma levels were upregulated in SLE patients and correlated with some clinical, laboratory characteristics such as proteinuria, pyuria, and may be a potential biomarker for SLE. After SHP2 inhibitor treatment, hepatosplenomegaly and histological severity of the kidney in lupus mice were improved. SHP2 inhibitor reversed DCs, Th1, and Th17 cells differentiation and downregulated inflammatory cytokines (IL-4, IL-6, IL-10, IL-17A, IFN-&#x3b3; and TNF-&#x3b1;) and autoantibodies (ANA, anti-dsDNA) production in pristane-lupus mice.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In summary, SHP2 correlated with SLE pathogenesis and promoted the development of lupus.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Chan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Su</LastName><ForeName>Lin-Chong</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Minda Hospital of Hubei Minzu University, 2 Wufengshan Road, Enshi, 445000, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>You-Yu</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, 25 Taiping Road, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>You-Qiang</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wang-Dong</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Evidence-Based Medicine, Southwest Medical University, 1 Xianglin Road, Luzhou, 646000, Sichuan, China. loutch123@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>An-Fang</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, 25 Taiping Road, Luzhou, 646000, Sichuan, China. loutch211@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81701606</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Inflamm Res</MedlineTA><NlmUniqueID>9508160</NlmUniqueID><ISSNLinking>1023-3830</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>26HZV48DT1</RegistryNumber><NameOfSubstance UI="C009042">pristane</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013729">Terpenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013729" MajorTopicYN="N">Terpenes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Lupus</Keyword><Keyword MajorTopicYN="N">SHP2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>11</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37351631</ArticleId><ArticleId IdType="doi">10.1007/s00011-023-01760-w</ArticleId><ArticleId IdType="pii">10.1007/s00011-023-01760-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang C, et al. Increased levels of sirtuin-1 in systemic lupus erythematosus. Int J Rheum Dis. 2022;25(8):869&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">35644944</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ci W, et al. Characteristics and risk factors of severe coronary artery disease in systemic lupus erythematosus: a multicenter, Chinese Rheumatism Date Center database study. Int J Rheum Dis. 2022;25(10):1186&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">35880514</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14402</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y. Systemic lupus erythematosus increases risk of incident atrial fibrillation: a systematic review and meta-analysis. Int J Rheum Dis. 2022;25(10):1097&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">35906745</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14403</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata K, et al. Up-regulation of TLR7-mediated IFN-&#x3b1; production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Front Immunol. 2018;9:1957.</Citation><ArticleIdList><ArticleId IdType="pubmed">30210502</ArticleId><ArticleId IdType="pmc">6121190</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2018.01957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244038</ArticleId><ArticleId IdType="doi">10.1146/annurev.immunol.19.1.275</ArticleId></ArticleIdList></Reference><Reference><Citation>Axtell RC, Raman C, Steinman L. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol. 2013;44(2):114&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22231516</ArticleId><ArticleId IdType="pmc">5478162</ArticleId><ArticleId IdType="doi">10.1007/s12016-011-8296-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol. 2007;27(1):47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">17336688</ArticleId><ArticleId IdType="pmc">1997284</ArticleId><ArticleId IdType="doi">10.1016/j.semnephrol.2006.09.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu CK. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res. 2000;10(4):279&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11191350</ArticleId><ArticleId IdType="doi">10.1038/sj.cr.7290055</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof P, et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92(4):441&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9491886</ArticleId><ArticleId IdType="doi">10.1016/S0092-8674(00)80938-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure. 1998;6(3):249&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9551546</ArticleId><ArticleId IdType="doi">10.1016/S0969-2126(98)00027-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankson R, et al. Therapeutic targeting of oncogenic tyrosine phosphatases. Cancer Res. 2017;77(21):5701&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28855209</ArticleId><ArticleId IdType="pmc">5827927</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-17-1510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu MF, et al. Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria. Sci Rep. 2017;7(1):461.</Citation><ArticleIdList><ArticleId IdType="pubmed">28352079</ArticleId><ArticleId IdType="pmc">5428720</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-00564-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei&#xdf;enberg SY, et al. Identification and characterization of post-activated B cells in systemic autoimmune diseases. Front Immunol. 2019;10:2136.</Citation><ArticleIdList><ArticleId IdType="pubmed">31616406</ArticleId><ArticleId IdType="pmc">6768969</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.02136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. J Clin Invest. 2016;126(6):2077&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">27183387</ArticleId><ArticleId IdType="pmc">4887187</ArticleId><ArticleId IdType="doi">10.1172/JCI87037</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119(8):700&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16887417</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2005.11.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27558659</ArticleId><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao P, et al. Phosphatase Shp2 exacerbates intestinal inflammation by disrupting macrophage responsiveness to interleukin-10. J Exp Med. 2019;216(2):337&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">30610104</ArticleId><ArticleId IdType="pmc">6363431</ArticleId><ArticleId IdType="doi">10.1084/jem.20181198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan R, Rasool M. Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr 61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis. Mol Immunol. 2017;91:134&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">28898718</ArticleId><ArticleId IdType="doi">10.1016/j.molimm.2017.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng JF, et al. Lentivirus-mediated silencing of Src homology 2 domain-containing protein tyrosine phosphatase 2 inhibits release of inflammatory cytokines and apoptosis in renal tubular epithelial cells via inhibition of the TLR4/NF-kB pathway in renal ischemia-reperfusion injury. Kidney Blood Press Res. 2018;43(4):1084&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">29991025</ArticleId><ArticleId IdType="doi">10.1159/000491565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisbona MP, et al. Noonan syndrome associated with systemic lupus erythematosus. Lupus. 2009;18(3):267&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19213867</ArticleId><ArticleId IdType="doi">10.1177/0961203308094996</ArticleId></ArticleIdList></Reference><Reference><Citation>Leventopoulos G, et al. Noonan syndrome and systemic lupus erythematosus in a patient with a novel KRAS mutation. Clin Exp Rheumatol. 2010;28(4):556&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20810036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Rangel E, et al. Systemic lupus erythematosus and other autoimmune disorders in children with Noonan syndrome. Am J Med Genet A. 2005;139(3):239&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16283670</ArticleId><ArticleId IdType="doi">10.1002/ajmg.a.31017</ArticleId></ArticleIdList></Reference><Reference><Citation>Alanay Y, Balc&#x131; S, Ozen S. Noonan syndrome and systemic lupus erythematosus: presentation in childhood. Clin Dysmorphol. 2004;13(3):161&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">15194952</ArticleId><ArticleId IdType="doi">10.1097/01.mcd.0000127467.04018.6d</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoroso A, et al. The unusual association of three autoimmune diseases in a patient with Noonan syndrome. J Adolesc Health. 2003;32(1):94&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12507808</ArticleId><ArticleId IdType="doi">10.1016/S1054-139X(02)00364-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, et al. Endogenous miR-204 protects the kidney against chronic injury in hypertension and diabetes. J Am Soc Nephrol. 2020;31(7):1539&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">32487559</ArticleId><ArticleId IdType="pmc">7350998</ArticleId><ArticleId IdType="doi">10.1681/ASN.2019101100</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, et al. SHP2 inhibitor PHPS1 ameliorates acute kidney injury by Erk1/2-STAT3 signaling in a combined murine hemorrhage followed by septic challenge model. Mol Med. 2020;26(1):89.</Citation><ArticleIdList><ArticleId IdType="pubmed">32957908</ArticleId><ArticleId IdType="pmc">7504828</ArticleId><ArticleId IdType="doi">10.1186/s10020-020-00210-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda N, et al. Differential expression of SHP2, a protein-tyrosine phosphatase with SRC homology-2 domains, in various types of renal tumour. Virchows Arch. 1998;433(4):331&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808435</ArticleId><ArticleId IdType="doi">10.1007/s004280050257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson CM, Sheibani N. Altered regulation of SHP-2 and PTP 1B tyrosine phosphatases in cystic kidneys from bcl-2<sup>&#x2212;</sup><sup>/</sup><sup>&#x2212;</sup> mice. Am J Physiol Renal Physiol. 2002;282(3):F442&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832424</ArticleId><ArticleId IdType="doi">10.1152/ajprenal.00184.2001</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng CC, et al. &#x3b1;-Actinin-4 recruits Shp2 into focal adhesions to potentiate ROCK2 activation in podocytes. Life Sci Alliance. 2022;5(11):e202201557.</Citation><ArticleIdList><ArticleId IdType="pubmed">36096674</ArticleId><ArticleId IdType="pmc">9468603</ArticleId><ArticleId IdType="doi">10.26508/lsa.202201557</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res. 2015;75(3):508&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">25480946</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-14-1215</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmond RJ, et al. The src homology 2 domain-containing tyrosine phosphatase 2 regulates primary T-dependent immune responses and Th cell differentiation. J Immunol. 2005;175(10):6498&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">16272304</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.175.10.6498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. SHP2 allosteric inhibitor TK-453 alleviates psoriasis-like skin inflammation in mice via inhibition of IL-23/Th17 axis. iScience. 2022;25(4):104009.</Citation><ArticleIdList><ArticleId IdType="pubmed">35310939</ArticleId><ArticleId IdType="pmc">8927994</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2022.104009</ArticleId></ArticleIdList></Reference><Reference><Citation>Frearson JA, Alexander DR. The phosphotyrosine phosphatase SHP-2 participates in a multimeric signaling complex and regulates T cell receptor (TCR) coupling to the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T cells. J Exp Med. 1998;187(9):1417&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9565634</ArticleId><ArticleId IdType="pmc">2212277</ArticleId><ArticleId IdType="doi">10.1084/jem.187.9.1417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TV, et al. Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J Immunol. 2006;177(9):5990&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17056523</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.177.9.5990</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Q, et al. Blocking initial infiltration of pioneer CD8(+) T cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice. Br J Pharmacol. 2014;171(7):1706&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24372081</ArticleId><ArticleId IdType="pmc">3966750</ArticleId><ArticleId IdType="doi">10.1111/bph.12565</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, et al. Tyrosine phosphatase Shp2 regulates p115RhoGEF/Rho-dependent dendritic cell migration. Cell Mol Immunol. 2021;18(3):755&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32350404</ArticleId><ArticleId IdType="doi">10.1038/s41423-020-0414-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark DN, et al. Cytokine inhibition as a strategy for treating systemic lupus erythematosus. Clin Immunol. 2013;148(3):335&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">23200699</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2012.11.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011;13(4):228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745419</ArticleId><ArticleId IdType="pmc">3239336</ArticleId><ArticleId IdType="doi">10.1186/ar3349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bixler SL, et al. Suppressed Th17 levels correlate with elevated PIAS3, SHP2, and SOCS3 expression in CD4 T cells during acute simian immunodeficiency virus infection. J Virol. 2013;87(12):7093&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">23596301</ArticleId><ArticleId IdType="pmc">3676085</ArticleId><ArticleId IdType="doi">10.1128/JVI.00600-13</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber DF, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med. 2005;11(9):933&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16127435</ArticleId><ArticleId IdType="doi">10.1038/nm1291</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford SM, Bottini N. Targeting tyrosine phosphatases: time to end the stigma. Trends Pharmacol Sci. 2017;38(6):524&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28412041</ArticleId><ArticleId IdType="pmc">5494996</ArticleId><ArticleId IdType="doi">10.1016/j.tips.2017.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Regen F, et al. Clozapine-induced agranulocytosis: evidence for an immune-mediated mechanism from a patient-specific in-vitro approach. Toxicol Appl Pharmacol. 2017;316:10&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939987</ArticleId><ArticleId IdType="doi">10.1016/j.taap.2016.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fizazi K, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27(15):2429&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">19364971</ArticleId><ArticleId IdType="doi">10.1200/JCO.2008.18.9811</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, et al. SH2 domain-containing phosphatase 2 inhibition attenuates osteoarthritis by maintaining homeostasis of cartilage metabolism via the docking protein 1/uridine phosphorylase 1/uridine cascade. Arthritis Rheumatol. 2022;74(3):462&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">34569725</ArticleId><ArticleId IdType="doi">10.1002/art.41988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, et al. Therapeutic effect of the injectable thermosensitive hydrogel loaded with SHP099 on intervertebral disc degeneration. Life Sci. 2021;266: 118891.</Citation><ArticleIdList><ArticleId IdType="pubmed">33310047</ArticleId><ArticleId IdType="doi">10.1016/j.lfs.2020.118891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein. J Med Chem. 2020;63(14):7510&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">32437146</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.0c00471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>